Ninety percent of migraine sufferers experience nausea, while 60 percent experience vomiting because of their migraine. As a result, today’s most common migraine treatments that are administered orally are less effective. Enter Zelrix, or NP101, which...

As Peter J. Boni highlighted this morning, despite volatile capital markets and a wobbly economy, Safeguard Scientifics continues to fire on all cylinders by realizing value through well-timed exit transactions and deploying capital in new growth opportunities. For...

The IPO Task Force unveiled a new effort to ease the IPO road for emerging companies in its report, “Rebuilding the IPO On-Ramp.” The report calls for an easing of regulations that it says are holding back emerging U.S. companies. Among its recommendations,...

Safeguard Scientifics will release its financial results for the third quarter ended September 30, 2011 prior to market open on Wednesday, October 26. At 9 a.m. EDT that morning, Safeguard will host a conference call and webcast on which Peter J. Boni,...

As another week draws to a close, we’d like to take a minute to look at some developments making their way around the Web and highlight some exciting Safeguard news. A report released last week by the National Venture Capital Association (NVCA) and...

This morning, we announced our second quarter 2011 financial results and reported on the exciting progress we’ve made this quarter. We deployed $45.8 million of capital in new and existing partner companies, including NovaSom, PixelOptics, and Alverix. We...